Bio-Techne Free Cash Flow (FCF) History (TECH)
Bio-Techne reported $256.6M in free cash flow for fiscal 2025, an increase of 8.66% from the previous fiscal year, with a free cash flow margin of 21.03%.
View full Bio-Techne company overviewBio-Techne free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-06-30 | $256.6M | $20.4M | +8.66% | +21.03% |
| 2024 | 2024-06-30 | $236.1M | $20.0M | +9.23% | +20.37% |
| 2023 | 2023-06-30 | $216.1M | −$64.2M | −22.90% | +19.02% |
| 2022 | 2022-06-30 | $280.4M | −$27.5M | −8.93% | +25.36% |
| 2021 | 2021-06-30 | $307.9M | $154.4M | +100.60% | +33.07% |
| 2020 | 2020-06-30 | $153.5M | −$2.7M | −1.75% | +20.78% |
| 2019 | 2019-06-30 | $156.2M | $6.8M | +4.53% | +21.88% |
| 2018 | 2018-06-30 | $149.4M | $20.9M | +16.25% | +23.24% |
| 2017 | 2017-06-30 | $128.5M | $1.3M | +1.01% | +22.83% |
| 2016 | 2016-06-30 | $127.3M | $7.8M | +6.53% | +25.50% |
| 2015 | 2015-06-30 | $119.5M | −$3.5M | −2.84% | +26.41% |
| 2014 | 2014-06-30 | $122.9M | $21.8M | +21.59% | +34.36% |
| 2013 | 2013-06-30 | $101.1M | −$19.6M | −16.25% | +32.56% |
| 2012 | 2012-06-30 | $120.7M | −$2.8M | −2.29% | +38.38% |
| 2011 | 2011-06-30 | $123.6M | $16.9M | +15.90% | +42.61% |
| 2010 | 2010-06-30 | $106.6M | $1.9M | +1.77% | +39.63% |
| 2009 | 2009-06-30 | $104.8M | — | — | +39.69% |
Bio-Techne quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q3 2026 | 2026-03-31 | $77.6M | $46.6M | +150.27% | +24.91% |
| Q2 2026 | 2025-12-31 | $76.5M | −$1.0M | −1.34% | +25.85% |
| Q1 2026 | 2025-09-30 | $22.2M | −$32.5M | −59.39% | +7.75% |
| Q4 2025 | 2025-06-30 | $93.3M | $35.8M | +62.23% | +29.44% |
| Q3 2025 | 2025-03-31 | $31.0M | −$33.5M | −51.98% | +9.80% |
| Q2 2025 | 2024-12-31 | $77.5M | $9.3M | +13.59% | +26.10% |
| Q1 2025 | 2024-09-30 | $54.7M | $8.9M | +19.49% | +18.90% |
| Q4 2024 | 2024-06-30 | $57.5M | −$15.0M | −20.74% | +18.79% |
| Q3 2024 | 2024-03-31 | $64.5M | $25.8M | +66.41% | +21.27% |
| Q2 2024 | 2023-12-31 | $68.3M | $10.0M | +17.12% | +25.04% |
| Q1 2024 | 2023-09-30 | $45.8M | −$734,000 | −1.58% | +16.53% |
| Q4 2023 | 2023-06-30 | $72.6M | −$16.6M | −18.60% | +24.08% |
| Q3 2023 | 2023-03-31 | $38.8M | −$19.2M | −33.16% | +13.19% |
| Q2 2023 | 2022-12-31 | $58.3M | −$32.5M | −35.84% | +21.46% |
| Q1 2023 | 2022-09-30 | $46.5M | $4.2M | +9.82% | +17.25% |
| Q4 2022 | 2022-06-30 | $89.1M | −$21.6M | −19.47% | +30.93% |
| Q3 2022 | 2022-03-31 | $58.0M | −$6.2M | −9.70% | +19.98% |
| Q2 2022 | 2021-12-31 | $90.8M | $13.0M | +16.71% | +33.73% |
| Q1 2022 | 2021-09-30 | $42.4M | −$12.7M | −23.07% | +16.44% |
| Q4 2021 | 2021-06-30 | $110.7M | $83.3M | +303.76% | +42.74% |
| Q3 2021 | 2021-03-31 | $64.3M | $24.1M | +59.91% | +26.39% |
| Q2 2021 | 2020-12-31 | $77.8M | $22.0M | +39.33% | +34.70% |
| Q1 2021 | 2020-09-30 | $55.1M | $25.1M | +83.48% | +26.97% |
| Q4 2020 | 2020-06-30 | $27.4M | −$16.8M | −38.04% | +15.59% |
| Q3 2020 | 2020-03-31 | $40.2M | $5.5M | +15.69% | +20.64% |
| Q2 2020 | 2019-12-31 | $55.9M | $13.9M | +33.12% | +30.20% |
| Q1 2020 | 2019-09-30 | $30.0M | −$5.2M | −14.87% | +16.38% |
| Q4 2019 | 2019-06-30 | $44.3M | −$14.8M | −25.02% | +23.09% |
| Q3 2019 | 2019-03-31 | $34.7M | $16.6M | +91.47% | +18.79% |
| Q2 2019 | 2018-12-31 | $42.0M | $9.1M | +27.74% | +24.04% |
| Q1 2019 | 2018-09-30 | $35.3M | −$4.2M | −10.56% | +21.63% |
| Q4 2018 | 2018-06-30 | $59.0M | $13.9M | +30.72% | +32.74% |
| Q3 2018 | 2018-03-31 | $18.1M | −$2.9M | −13.63% | +11.06% |
| Q2 2018 | 2017-12-31 | $32.8M | −$5.5M | −14.30% | +21.31% |
| Q1 2018 | 2017-09-30 | $39.4M | $15.4M | +63.85% | +27.26% |
| Q4 2017 | 2017-06-30 | $45.2M | $11.6M | +34.40% | +28.84% |
| Q3 2017 | 2017-03-31 | $21.0M | −$13.3M | −38.77% | +14.58% |
| Q2 2017 | 2016-12-31 | $38.3M | $4.7M | +13.89% | +29.08% |
| Q1 2017 | 2016-09-30 | $24.1M | −$1.7M | −6.43% | +18.43% |
| Q4 2016 | 2016-06-30 | $33.6M | $3.4M | +11.22% | +24.93% |
| Q3 2016 | 2016-03-31 | $34.3M | $8.4M | +32.68% | +26.19% |
| Q2 2016 | 2015-12-31 | $33.7M | $1.1M | +3.28% | +27.83% |
| Q1 2016 | 2015-09-30 | $25.7M | −$5.1M | −16.55% | +22.88% |
| Q4 2015 | 2015-06-30 | $30.2M | −$5.6M | −15.67% | +25.67% |
| Q3 2015 | 2015-03-31 | $25.9M | −$4.8M | −15.72% | +22.65% |
| Q2 2015 | 2014-12-31 | $32.6M | $4.9M | +17.74% | +29.11% |
| Q1 2015 | 2014-09-30 | $30.8M | $2.0M | +7.09% | +28.41% |
| Q4 2014 | 2014-06-30 | $35.8M | $11.2M | +45.36% | +38.71% |
| Q3 2014 | 2014-03-31 | $30.7M | $4.0M | +15.09% | +32.10% |
| Q2 2014 | 2013-12-31 | $27.7M | $4.6M | +19.98% | +32.94% |
| Q1 2014 | 2013-09-30 | $28.8M | $2.0M | +7.57% | +33.59% |
| Q4 2013 | 2013-06-30 | $24.6M | −$11.6M | −32.08% | +31.00% |
| Q3 2013 | 2013-03-31 | $26.7M | −$6.2M | −18.93% | +32.91% |
| Q2 2013 | 2012-12-31 | $23.1M | $4.8M | +26.48% | +30.72% |
| Q1 2013 | 2012-09-30 | $26.7M | −$6.6M | −19.76% | +35.65% |
| Q4 2012 | 2012-06-30 | $36.3M | $2.9M | +8.63% | +46.11% |
| Q3 2012 | 2012-03-31 | $32.9M | $1.1M | +3.40% | +39.32% |
| Q2 2012 | 2011-12-31 | $18.2M | −$10.5M | −36.50% | +24.43% |
| Q1 2012 | 2011-09-30 | $33.3M | $3.7M | +12.43% | +42.96% |
| Q4 2011 | 2011-06-30 | $33.4M | $2.7M | +8.94% | +42.80% |
| Q3 2011 | 2011-03-31 | $31.8M | $9.9M | +45.50% | +41.69% |
| Q2 2011 | 2010-12-31 | $28.7M | $2.1M | +7.80% | +42.42% |
| Q1 2011 | 2010-09-30 | $29.7M | $2.2M | +7.96% | +43.64% |
| Q4 2010 | 2010-06-30 | $30.7M | — | — | +45.95% |
| Q3 2010 | 2010-03-31 | $21.9M | — | — | +31.09% |
| Q2 2010 | 2009-12-31 | $26.6M | — | — | +40.66% |
| Q1 2010 | 2009-09-30 | $27.5M | — | — | +41.28% |
Bio-Techne free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from $153.5M to $256.6M, a compound annual growth rate of 10.82%. Bio-Techne's latest reported quarter, Q3 2026, generated $77.6M in free cash flow, an increase of 150.27% year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Bio-Techne filings at SEC.gov ↗